Which strategy is more effective for the treatment of cardiovascular disease: High-dose angiotensin II type 1 receptor antagonist monotherapy or combination therapy?

American Journal of Cardiovascular Drugs

Volumn 8, Issue 2, 2008, Pages 88-90

  Miura, Shin Ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin II 1 receptor antagonists, therapeutic use; Cardiovascular disorders, treatment; Stent thrombosis, prevention; Valsartan, therapeutic use

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HEART INJURY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; NOTE; PRIORITY JOURNAL; PROTEINURIA; RESTENOSIS; TREATMENT PLANNING;

EID: 42449098152     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256586     Document Type: Note

References (18)

1. Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003; 26: 937-43
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1751-62
3. Stergiou GS, Makris T, Papavasiliou M, et al. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005; 23: 883-9
4. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-24
5. Anan F, Takahashi N, Ooie T, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005; 61: 353-9
6. Uzu T, Sawaguchi M, Maegawa H, et al., on behalf of the Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-3
7. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6
8. McMurray JJ, Ostergren J, Swedberg K, et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71
9. Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998; 20: 1106-14
10. Pool JL, Glazer R, Chiang YT, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999; 13: 275-81
11. Peters S. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of baremetal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs 2008; 8: 83-7
12. Peters S, Götting B, Trümmel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invas Cardiol 2001; 13: 93-7
13. Radke PW, Figulla HR, Drexler H, et al., on behalf of the AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006; 152: 761.e1-6
14. Iwata A, Miura S, Imaizumi S, et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 32-8
15. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115-21
16. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86
17. Matsuda H, Hayashi K, Homma K, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875-80
18. Wang L, Li GH, Chen H, et al. Effect of valsartan-eluting stents on the expression of angiotensin II type 2 receptor. Chin Med J 2006; 119: 601-4